Analyst Coverage and Reports

Date Analyst Headline
15-Oct-20 Jonas Peculias
15-Oct-20 Analyst: Jonas Peculias

This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

Continue
17-Sep-20 Jonas Peculias
17-Sep-20 Analyst: Jonas Peculias

This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

Continue
13-Aug-20 Jonas Peculias
13-Aug-20 Analyst: Jonas Peculias

This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

Continue
16-Jul-20 Jonas Peculias
16-Jul-20 Analyst: Jonas Peculias

This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

Continue
11-Jun-20 Jonas Peculias
11-Jun-20 Analyst: Jonas Peculias

This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research
Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

Continue
14-May-20 Jonas Peculias
14-May-20 Analyst: Jonas Peculias

This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research
Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

Continue
17-Apr-20 Jonas Peculias
17-Apr-20 Analyst: Jonas Peculias

This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research
Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

Continue
19-Mar-20 Jonas Peculias
19-Mar-20 Analyst: Jonas Peculias

This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research

Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

Continue
19-Feb-20 Jonas Peculias
19-Feb-20 Analyst: Jonas Peculias

This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research

Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

Continue
05-Feb-20 John Hester
05-Feb-20 Analyst: John Hester
Bell Potter: “First Response in Cognition”
This report is for limited distribution by Bell Potter to selected Professional Investors and Sophisticated Wholesale Investors. Please email info@actinogen.com.au if you would like to receive a copy.
22-Nov-19 Jonas Peculias
22-Nov-19 Analyst: Jonas Peculias

This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research

Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

Continue
17-Oct-19 Jonas Peculias
17-Oct-19 Analyst: Jonas Peculias

This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research

Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

Continue
16-Oct-19 Jonas Peculias
16-Oct-19 Analyst: Jonas Peculias

This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research

Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

Continue
19-Sep-19 Jonas Peculias
19-Sep-19 Analyst: Jonas Peculias

This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research

Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

Continue
22-Aug-19 Jonas Peculias
22-Aug-19 Analyst: Jonas Peculias

This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research

Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

Continue
08-May-19 Jonas Peculias
08-May-19 Analyst: Jonas Peculias

This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research

Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

Continue
18-Apr-19 Jonas Peculias
18-Apr-19 Analyst: Jonas Peculias

This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research

Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

Continue
18-Mar-19 Jonas Peculias
18-Mar-19 Analyst: Jonas Peculias

This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison. The report solely reflects the views of Edison.

Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

Continue
04-Jun-18 Chhai Ung
04-Jun-18 Analyst: Chhai Ung

This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Red Leaf Securities, an Authorised Representative of BR Securities. The report solely reflects the views of Red Leaf Securities.

Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Red Leaf Securities at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

Continue
07-May-18 Red Leaf Securities
07-May-18 Analyst: Red Leaf Securities

This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Red Leaf Securities, an Authorised Representative of BR Securities. The report solely reflects the views of Red Leaf Securities.

Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Red Leaf Securities at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

Continue
10-Apr-18 Stuart Roberts
10-Apr-18 Analyst: Stuart Roberts

This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by NDF Research, an Authorised Representative of BR Securities Australia Pty Ltd. The report solely reflects the views of NDF Research.

Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of NDF Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

Continue
27-Sep-16 Alastair Murray
27-Sep-16 Analyst: Alastair Murray

This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Baker Young Stockbrokers Limited. The report solely reflects the views of Baker Young Stockbrokers Limited.

Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Baker Young Stockbrokers Limited at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

Continue
05-Jul-16 Red Chip
05-Jul-16 Analyst: Red Chip

This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by RedChip Companies, Inc. The report solely reflects the views of RedChip Companies, Inc..

Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of RedChip Companies, Inc. at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

Continue
11-Aug-15 Dirk van Dissel & Alastair Murray
11-Aug-15 Analyst: Dirk van Dissel & Alastair Murray

This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Baker Young Stockbrokers Limited. The report solely reflects the views of Baker Young Stockbrokers Limited.

Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Baker Young Stockbrokers Limited at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

Continue